Safety and feasibility of intravenous fresh adipose-derived mesenchymal stem cells in secondary progressive multiple sclerosis: phase I/IIa clinical results
High-dose fresh AT-MSCs appear safe and well-tolerated in SPMS patients, with promising exploratory clinical benefits. These findings support AT-MSCs as a potential multiple sclerosis therapy. Trial registration Registered with the Iranian Registry of Clinical Trials (Reference: IRCT20091127002778N1 at 2018-01-10).
Authors
- Ali Nikkhah (ORCID: https://orcid.org/0000-0001-9347-5053)
- Karim Nikkhah
- Marjan Erfani
- Fatemeh Ayoobi (ORCID: https://orcid.org/0000-0003-2901-7327)
- Nafiseh Tabasi (ORCID: https://orcid.org/0000-0001-7068-6325)
- Houshang Amiri (ORCID: https://orcid.org/0000-0003-4086-5255)
- Hojjat Naderi-Meshkin
- Fahimeh Lavi Arab
- Mahmoud Mahmoudi
- Forouzan Yousefi
- Mahdi Mirahmadi
- Fatemeh Faraji
Institutions
- Iran University of Medical Sciences (IR)
- Mashhad University of Medical Sciences (IR)
- Kerman University of Medical Sciences (IR)
- Academic Center for Education, Culture and Research (IR)
- Health Service Executive (IE)
- Biotechnology Research Center (IR)
- St. Davnet's Hospital (IE)
- Rafsanjan University of Medical Sciences (IR)
- Amsterdam UMC Location Vrije Universiteit Amsterdam (NL)
Publication Details
- Journal
- Stem Cell Research & Therapy
- Published
- 2026-02-22
- DOI
- https://doi.org/10.1186/s13287-026-04933-6
- Primary Topic
- Mesenchymal stem cell research
- Type
- article
- Field-Weighted Citation Impact
- 0.00